A calcium-channel blocker, benidipine, improves forearm reactive hyperemia in patients with essential hypertension.
The pathophysiological role of endothelial cells is important in the mechanism of progression of atherosclerosis and improvement of endothelial function may be important for cardiovascular morbidity. Calcium antagonists are reported to have protective effects on the endothelium in vitro and in vivo. In this clinical study, we investigated the effect of calcium antagonist, benidipine, on endothelial function in the patients with essential hypertension, which causes endothelial dysfunction. Twenty-five patients with hypertension without other risk factors for atherosclerosis were treated with monotherapy (8 mg benidipine, n=25) for 8 weeks. Blood pressure was reduced significantly. Endothelial function was evaluated using forearm blood flow by strain-gauge plethysmography after 8 weeks of treatment. Changes in vasodilator response to reactive hyperemia were significantly improved (p<0.01), while the response to nitroglycerin was not changed, suggesting the improvement of endothelial function. Moreover, we focused on hepatocyte growth factor (HGF), which is a novel angiogenic growth factor with an anti-apoptotic action on endothelial cells, and evaluated involvement of HGF in improvement of endothelial function. Serum HGF concentration in subjects treated with benidipine was significantly elevated at 8 weeks (p<0.05). Overall, these results demonstrated that benidipine improved endothelial dysfunction in patients with hypertension. Interestingly, an increase in serum HGF concentration by benidipine might contribute to the improvement of endothelial dysfunction.
Makino
Hirofumi
H
Department of Geriatric Medicine, Osaka University Medical School, Osaka, Japan.
Aoki
Motokuni
M
Hashiya
Naotaka
N
Yamasaki
Keita
K
Shimizu
Hideo
H
Miwa
Ken
K
Ogihara
Toshio
T
Morishita
Ryuichi
R
D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004095:Dihydropyridines / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D005542:Forearm / Q000473:pathology*; D017228:Hepatocyte Growth Factor / Q000378:metabolism; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D005996:Nitroglycerin / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D014665:Vasodilator Agents; C061004:benidipine; D017228:Hepatocyte Growth Factor; D005996:Nitroglycerin